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Abstract
Evaluation of defibrillation threshold is a standard of care during implantation of implantable 
cardioverter defibrillator. High defibrillation thresholds are often encountered and pose a 
challenge to electrophysiologists to improve the defibrillation threshold. We describe a case 
series where defibrillation thresholds were improved after implanting a defibrillation lead in the 
azygos   vein.
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Introduction
 
Implantable Cardioverter defibrillator (ICD) has evolved as an important therapy to prevent 
sudden cardiac death. Early experience with ICDs revealed cases of sudden death in patients due 
ineffective defibrillation as a result of inadequate defibrillation thresholds (DFT) safety margins 
[1-4]. Subsequently it has been a standard of care to check the DFTs when a new ICD is placed. 
DFT is defined as the lowest amount of energy delivered by the ICD to successfully terminate 
two episodes of induced ventricular fibrillation. DFTs can be measured by multiple techniques 
but   a   safety   margin   of   10   joules   for   defibrillation   is   standard   of   care   [5-9].
High DFT is defined as a DFT value less than 10 joules lower than the maximum out put of 
defibrillator generator. Studies have demonstrated that a significant percentage of patients (6 to 
16 %) have higher DFTs [3]. DFTs can be reduced by multiple mechanisms. We describe a case 
series of 3 patients where leads were placed in azygos vein to improve defibrillation threshold.
Case   1:                                                                      
An 88 year  old male with a history of dilated  cardiomyopathy,  severe left ventricular 
dysfunction (Ejection fraction of 30 %) with intraventricular conduction delay had symptomatic 
heart failure in spite of being on maximal medical therapy and a cardiac resynchronization 
therapy with defibrillator back up was recommended as he was functional at base line.
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After informed consent was obtained, patient was prepared and draped in standard sterile 
fashion. Venous access was obtained through left axillary vein by modified seldinger technique, 
introducers were placed, leads were advanced and positioned in the right ventricular apex (0181 
ICD lead Guidant), right atrial appendage (4086 Guidant) and via the coronary sinus in the 
posterior lateral aspect of the left ventricle (4517 Guidant). After demonstration of appropriate 
pacing sensing function, the leads were anchored to pectoralis muscle and connected to a 
Guidant pulse generator (H 219). The leads along with pulse generator were placed inside the 
prepectoral pocket and the defibrillation threshold was assessed. There was difficulty in 
defibrillating at initial polarity and reversed polarity at 21 and 31 joules. A separate Superior 
vena cava (SVC) coil was placed at the juncture of the SVC and right atrium which did not 
improve the defibrillation threshold in either polarity. Subsequently the azygos vein was 
cannulated utilizing a Rapido IC 90, then a long sheath was placed and a Transvene lead (6937 
A-Medtronic) was placed in azygos vein and the patient was successfully defibrillated at 31 
joules (Figure 1 A). Post operative chest x-ray confirmed the position of lead (Figure 2 A)
Figure 1: A. Transvenous lead in azygous vein; B. RAO view showing origin of azygous vein; 
C. Posterior course of azygous vein; D. Lateral view of azygous vein.
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Figure 2: Chest X-ray showing the position of azygous vein lead
Case   2                                                                                    
A 42 yr old male with a history of dilated cardiomyopathy and severe left ventricular dysfunction 
who had previously underwent ICD placement for primary prevention presented after receiving 
shock for ventricular tachycardia. Upon device interrogation sensing and impedance were within 
normal limits but telemetry revealed inconsistent termination of ventricular tachycardia. In light of 
these findings it was felt that adding a shock lead in superior vena cava or azygos vein will help to 
improve DFT. Prior to the procedure DFT was assessed and 10 joule safety margin was not 
demonstrated. Vascular access was obtained through the left axillary vein and a Transvene lead 
(6937 A-Medtronic) was advanced and placed in SVC. Defibrillation threshold was assessed and 
there was inability to shock the patient both at 21 joules and 31 joules at initial and reverse 
polarity. Subsequently the Transvene lead (6937 A-Medtronic) was advanced to the azygos vein. 
Defibrillation was successfully achieved at 21 joules. Post operative chest x-ray confirmed lead 
position   (Figure   2   B)                                                                          
Case   3                                                                                      
A 30-year-old male with a  history of sickle cell anemia,  left ventricular dysfunction with (EF: 
20% to 30%) was found to have episodes of nonsustained ventricular tachycardia. A single 
chamber ICD was recommended as a primary prevention against sudden cardiac death. After 
informed consent vascular access was obtained using modified seldinger technique and  right 
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ventricular lead was placed and then secured to ICD pulse generator. Defibrillation threshold was 
assessed and there was inability to shock the patient both at 21 joules, 31 joules and 41 joules in 
initial and reverse polarity. DFT did not improve even after placing Transvene lead (6937A 
-Medtronic) in the SVC. Subsequently after the azygos vein was cannulated and the Transvene 
lead (6937 A-Medtronic) was advanced and positioned in the azygos vein defibrillation could be 
successfully achieved at 21 joules. Post operative chest x-rays confirmed lead position (Figure 2C 
and  2D)                                                                                        
Azygos vein Cannulation Technique                                                                                             
After the setting the camera at 25° RAO view a Guidant Rapido IC 90 is advanced and a clock 
wise torque is performed once the catheter is in the proximal SVC. A 20 cc syringe is utilized with 
a 50:50 dye mixture and once the distal portion of catheter is in a side branch, venography is 
performed (RAO/LAO view). After confirming the position of catheter in azygos vein a stiff wire 
is advanced and Rapido IC 90 is exchanged for a long safe sheath which is advanced and 
positioned in azygos vein (Figure 1 B, C, D). A Medtronic Transvene lead (6937 A) is advanced 
and positioned in the azygos vein and then the sheath is gently peeled away.               
Results
In all the patients adding a defibrillation coil in the azygos vein helped in achieving adequate 
defibrillation threshold. The average flouro time was 2 -4 minutes.  There were no procedure 
related complications and no lead displacement after a mean follow up of 18 months (14-24 
months).  
Discussion
The prevalence of sudden cardiac death in USA is estimated to be 400,000 to 500,000 patients 
annually [6]. ICDs have evolved as a significant tool for the primary prevention of sudden cardiac 
death and a have been shown to improve survival in patients who are at high risk for ventricular 
arrhythmias   [7,8].                                                                                          
Studies have demonstrated that patients with QRS prolongation in hypertrophic cardiomyopathy, 
non ischemic  dilated cardiomyopathy  and patients who are suitable for resynchronization 
defibrillators may have higher DFTs [10,11]. Earlier studies have also demonstrated the  clinical 
characteristics   that   identify   high   defibrillation   thresholds   are   NYHA   (New   York   Heart 
Association) Class III, IV, low ejection fraction, no previous history of bypass surgery, prior 
amiodarone use preoperatively (in the last 6 weeks), and presenting with ventricular fibrillation 
[16].
DFTs can be reduced by multiple mechanisms like active can technology, repositioning of right 
ventricular lead, biphasic shock wave forms, and implantation of subcutaneous arrays [10,14,15]. 
DFTs using the "active can" might be influenced by the site of implantation and possibly need 
additional coils to improve DFTs [17]. Subcutaneous array placement can be a technical challenge 
to the clinician and also can be cause of discomfort to the patient.                            
The azygos vein in adult is the vessel which persists from the fetal right posterior cardinal and 
supracardinal veins. It transports deoxygenated blood from the posterior walls of the thorax and 
abdomen into the superior vena cava.   It usually starts opposite the first or second lumbar 
vertebrae and is formed by the union of the ascending lumbar veins with the right subcostal vein 
and enters the thorax through aortic hiatus of diaphragm. Subsequently it ascends in the posterior 
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mediastinum arching over the right main bronchus and root of the right lung and then joins 
superior venacava before that vessel pierces the epicardium. Studies have demonstrated that as the 
electrode is located posterior to the heart the shock vector probably better encompasses the mass 
of myocardium that is posterior to the RV coil, the SVC coil and the casing of the ICD generator 
[12,13]. Cooper et al demonstrated that the success rate of improving DFTs is similar in both 
azygos vein leads and subcutaneous leads [13]. This procedure is safe and earlier case series also 
did not report any complications [12,13].                                                                               
Conclusion
In patients with high DFTs azygos vein lead placement is a safe option to lower DFTs. 
Cannulation of the azygos vein is possible using readily available tools for lead placement and is a 
less invasive alternative to epicardial shocking lead placement in patients who are difficult to 
achieve successful defibrillation. Larger studies are needed to further investigate this technique.
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